DelMar Pharmaceuticals (DMPI) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to DelMar Pharmaceuticals (DMPIResearch Report) yesterday and set a price target of $2.00. The company’s shares closed last Friday at $1.06.

According to, McCarthy is a 5-star analyst with an average return of 12.5% and a 45.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Interpace Diagnostics Group, and SELLAS Life Sciences Group.

DelMar Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.

See today’s analyst top recommended stocks >>

Based on DelMar Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.96 million. In comparison, last year the company had a GAAP net loss of $1.66 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.